drugset / Trial / NCT03200093

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093

Phase 4 Terminated 65 enrolled Rochester General Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.

Timeline

Start
2017-06-08
Primary completion
2021-04-22
Completion
2021-04-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 125 mg Oral